Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Core Insights - Metsera, Inc. is advancing its clinical-stage pipeline focused on obesity and metabolic diseases, with significant milestones expected in 2025 [2][3] Pipeline Highlights - MET-097i is in three ongoing Phase 2b trials, with preliminary results from VESPER-1 expected in mid-2025 and a Phase 3 initiation planned for late 2025 [4][6] - MET-233i is in Phase 1 trials, with five-week monotherapy data expected in Q2 2025 and additional readouts planned for late 2025 [5][6] - The oral formulation MET-097o has been accelerated, with four-week data expected in late 2025 [7][15] Financial Performance - As of March 31, 2025, cash and cash equivalents were $588.3 million, up from $352.4 million at the end of 2024, providing a runway into 2027 [8] - Research and development expenses for Q1 2025 were $57.2 million, significantly higher than $17.8 million in Q1 2024, driven by product candidate development costs [9] - General and administrative expenses increased to $8.6 million in Q1 2025 from $4.1 million in Q1 2024, primarily due to personnel-related costs [10] Organizational Updates - Jon P. Stonehouse was appointed as a Class III director and member of the Audit Committee, bringing extensive biopharmaceutical industry experience [13] - Matthew Lang was appointed as Chief Legal Officer, with a strong background in legal and business roles within the biopharmaceutical sector [14] Manufacturing and Collaboration - Metsera's collaboration with Amneal is progressing, with new facilities in India dedicated to peptide synthesis and sterile fill-finish manufacturing [12]